NASDAQ:AKTX
Akari Therapeutics Plc
Akari Therapeutics Plc reported net income of −$17.3M in fiscal 2025. The diluted share count rose 181.8%.Summary generated from Akari Therapeutics Plc's SEC filings. Latest annual report filed Mar 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−68.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+181.8%
Financials
| Item | 2015 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −31 | −23 | −17 | −22 | −17 |
| Net income | −45 | −18 | −10 | −20 | −17 |
| Free cash flow | −5 | n/a | n/a | n/a | n/a |
Recent filings
- DEF 14AProxy statement
Oct 1, 2026 - 4Insider transaction report
Oct 1, 2026 - 8-KDirector or officer change
Oct 1, 2026 - 4Insider transaction report
Aug 19, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of a shareholder vote
Jul 2, 2026 - 8-KEntry into a material agreement
Jun 26, 2026